Phospho-EFNB1 (Y317) Antibody

What is EFNB1 and what is the significance of its Y317 phosphorylation?

EFNB1 (Ephrin-B1) is a transmembrane ligand of the Eph receptor family involved in cell-cell communication, axon guidance, and cell adhesion. The protein has a molecular weight of approximately 38 kDa in its canonical form and is 346 amino acids in length . The phosphorylation of tyrosine 317 (Y317) represents a specific post-translational modification that regulates EFNB1's signaling capabilities and protein interactions. This phosphorylation site is particularly important because it influences EFNB1's association with ERBB family receptors and impacts downstream signaling pathways, including ERK1/2 activation . To detect this specific phosphorylation state, researchers utilize phospho-specific antibodies that recognize only the phosphorylated form of Y317.

How does phosphorylated EFNB1 (Y317) differ functionally from non-phosphorylated EFNB1?

Phosphorylated EFNB1 demonstrates distinct subcellular localization and functional properties compared to its non-phosphorylated counterpart. Research has shown that phosphorylated EFNB1 (at tyrosines including Y317) is largely excluded from the mitotic spindle during cell division, while non-phosphorylated forms appear to associate with the spindle . Immunofluorescence studies reveal that phosphorylated EFNB1 exists predominantly as puncta at the cell surface and in the cytoplasm, exhibiting a distinctly different staining pattern compared to antibodies that recognize non-phospho-specific epitopes . This differential localization suggests important functional consequences, as phosphorylated EFNB1 appears to enhance associations with ERBB receptors and potentiate ERK1/2 signaling pathways .

What is the relationship between PTPN13 and EFNB1 phosphorylation?

PTPN13 (Protein Tyrosine Phosphatase Non-Receptor Type 13) is a phosphatase that directly regulates EFNB1 phosphorylation status. Research demonstrates that:

• When PTPN13 is functional, it reduces EFNB1 phosphorylation

• In the absence of PTPN13 function, EFNB1 phosphorylation is enhanced

• Loss of PTPN13 function potentiates ERK1/2 signaling

This mechanism has been demonstrated through transfection experiments in HEK293 cells, where expression of wildtype PTPN13 decreased EFNB1 phosphorylation without altering its association with ERBB1. Conversely, expression of a phosphatase-null PTPN13 mutant (PTPN13 C/S) increased EFNB1 phosphorylation and its association with ERBB1, initiating ERK1/2 phosphorylation . This regulatory relationship is particularly significant in cancer contexts, as HPV16 E6 oncoprotein has been shown to target PTPN13 for degradation, potentially contributing to enhanced EFNB1 phosphorylation and signaling in HPV-associated cancers .

What are the optimal applications for detecting phospho-EFNB1 (Y317)?

Based on technical documentation and research protocols, the following applications are recommended for phospho-EFNB1 (Y317) detection:

When performing Western Blot analysis, researchers should expect to detect bands at approximately 38-45 kDa, representing the canonical EFNB1 protein with phosphorylation at Y317 . Sample preparation is critical, and lysates should be prepared with phosphatase inhibitors to preserve the phosphorylation state during extraction. For optimal results, blocking with BSA rather than milk is recommended, as milk contains phosphoproteins that may interfere with phospho-specific antibody binding.

How can I validate the specificity of my phospho-EFNB1 (Y317) antibody?

To ensure experimental rigor, validation of phospho-EFNB1 (Y317) antibody specificity should include the following steps:

• Phosphatase treatment control: Divide your sample and treat half with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show diminished signal in the treated sample.

• Peptide competition assay: Pre-incubate the antibody with the phosphorylated immunogenic peptide before application to your sample. This should abolish specific binding.

• Phosphorylation-dependent shifts: Use treatments known to modulate EFNB1 phosphorylation (such as PTPN13 overexpression or knockdown) to demonstrate signal modulation .

• Cross-reactivity assessment: Test the antibody against related phospho-epitopes, particularly those on EFNB2 and EFNB3, as some phospho-antibodies recognize conserved sites across multiple Ephrin family members .

• Subcellular localization verification: Use immunofluorescence to confirm that staining patterns match the expected distribution of phosphorylated EFNB1 (punctate membrane and cytoplasmic localization rather than spindle association during mitosis) .

What experimental controls should be included when studying EFNB1 phosphorylation dynamics?

When investigating EFNB1 phosphorylation, robust experimental design requires multiple controls:

• Positive control samples: Cells or tissues with confirmed EFNB1 expression and Y317 phosphorylation. Research indicates that cells expressing HPV16 E6 demonstrate enhanced EFNB1 phosphorylation due to PTPN13 degradation .

• Negative control samples: EFNB1 knockdown or knockout samples to confirm antibody specificity.

• Phosphorylation state controls:

  • Treatment with phosphatase inhibitors (e.g., sodium orthovanadate) to maximize phosphorylation

  • Treatment with phosphatase to abolish phosphorylation

  • Expression of PTPN13 wildtype vs. phosphatase-null mutants to modulate phosphorylation

• Multiple antibody approach: Use antibodies recognizing different EFNB1 epitopes (extracellular domain, intracellular non-phospho epitopes, and different phosphorylation sites) to comprehensively characterize EFNB1 status .

• Cell cycle synchronization: For studies involving mitotic spindle association, include protocols to synchronize cells at different cell cycle stages to properly assess phospho-EFNB1 distribution throughout cell division .

How does the association between ERBB receptors and EFNB1 change with phosphorylation status?

Research indicates complex dynamics in the interaction between ERBB receptors and EFNB1 that are influenced by phosphorylation:

• Both phosphorylated and non-phosphorylated forms of EFNB1 can associate with ERBB1 (EGFR) and ERBB2, but phosphorylated EFNB1 appears to associate more readily with ERBB1 .

• The interaction domains have been mapped through deletion and mutation studies:

  • For ERBB1, the second transmembrane motif (A661I G665I region) mediates the EFNB1 association

  • ERBB1's extracellular ligand binding domains are not required for EFNB1 association

• Targeting ERBB receptors with antibody therapies (cetuximab for ERBB1, trastuzumab for ERBB2) results in a shift in ERBB/EFNB1 complexes rather than complete disruption, allowing persistent EFNB1 signaling despite receptor blockade .

These findings suggest that the phosphorylation state of EFNB1 modulates not only its binding affinity for ERBB receptors but also influences the composition and dynamics of signaling complexes, potentially contributing to therapeutic resistance mechanisms.

What is the relationship between EFNB1 phosphorylation and its subcellular localization during mitosis?

EFNB1 exhibits distinct phosphorylation-dependent subcellular distribution patterns during mitosis:

• Phosphorylated EFNB1: Immunofluorescence studies using phospho-specific antibodies (including those recognizing phosphorylated Y317, Y324, and Y331) demonstrate that phosphorylated EFNB1 is largely excluded from the mitotic spindle during cell division. Instead, it localizes predominantly at the cell membrane and as cytoplasmic puncta .

• Non-phosphorylated EFNB1: In contrast, when detected with antibodies recognizing non-phospho-specific intracellular epitopes, EFNB1 demonstrates clear association with the mitotic spindle and co-localizes with gamma-tubulin .

• EFNB1 processing and localization: Research suggests that full-length EFNB1 is not associated with the mitotic spindle. Rather, a cleaved, unphosphorylated cytoplasmic fragment appears to be the predominant spindle-associated form .

The mechanistic significance of this differential localization remains an active area of investigation, with potential implications for understanding how EFNB1 might influence cell division processes and chromosome segregation.

How does EFNB1 processing (ectodomain shedding) relate to its phosphorylation state?

EFNB1 undergoes complex processing through ectodomain shedding and subsequent intracellular domain processing, which interacts with its phosphorylation status:

• Full-length EFNB1 (approximately 55 kDa) can be cleaved by matrix metalloproteases in a process known as ectodomain shedding, generating a C-terminal membrane-tethered fragment (CTF, 14-17 kDa) .

• This CTF can be further processed by gamma-secretase, liberating the intracellular domain (ICD) .

• Research suggests differential localization and function between full-length and processed forms:

  • Antibodies recognizing the extracellular domain do not stain the mitotic spindle

  • Antibodies recognizing intracellular epitopes show strong spindle staining

  • Phospho-specific antibodies (including Y317) show exclusion from the spindle

These findings suggest a model where EFNB1 processing and phosphorylation status work in concert to regulate its subcellular distribution and function. The molecular mechanisms controlling this interplay between processing and phosphorylation represent an important area for future research.

How does EFNB1 contribute to resistance against EGFR-targeted therapies in HNSCC?

Research has uncovered an important role for EFNB1 in mediating resistance to EGFR-targeted therapies in head and neck squamous cell carcinoma (HNSCC):

• Despite most HNSCC overexpressing ERBB1/EGFR, targeted therapies such as cetuximab have yielded disappointing clinical results .

• Mechanistic studies reveal that while cetuximab potently blocks EGFR/ERBB1 activation, it does not attenuate EFNB1 activation or downstream ERK1/2 phosphorylation .

• The persistence of EFNB1 signaling occurs through a novel mechanism: cetuximab drives a shift in EGFR dimerization partners within the signaling complex rather than completely disrupting signaling .

• This partner rearrangement allows persistent pathway activation despite targeted receptor blockade, suggesting that EFNB1 functions as part of the EGFR signaling complex and can maintain downstream signaling even when EGFR is inhibited .

This research provides a molecular explanation for therapeutic failures and suggests that targeting EFNB1 in combination with EGFR inhibitors might be a more effective therapeutic strategy for HNSCC.

What experimental evidence supports targeting EFNB1 as a therapeutic approach in cancer?

Several lines of experimental evidence support the potential of EFNB1 as a therapeutic target:

• In vivo tumor growth studies: Knockdown of EFNB1 significantly slowed tumor growth and improved survival in a murine model of HNSCC, suggesting a substantial contribution of EFNB1 signaling to HNSCC development .

• Resistance mechanism elucidation: EFNB1 signaling persists in the presence of cetuximab (anti-EGFR) and trastuzumab (anti-ERBB2), indicating that EFNB1 can maintain oncogenic signaling despite current targeted therapies .

• Signaling pathway impact: Studies demonstrate that EFNB1 phosphorylation correlates with enhanced ERK1/2 activation, a pathway critical for cancer cell proliferation and survival .

• Regulatory context: HPV oncoproteins target the negative regulator of EFNB1 (PTPN13) for degradation, suggesting that EFNB1 hyperactivation is selected for during oncogenesis .

These findings collectively suggest that EFNB1 represents a promising therapeutic target, particularly in contexts where ERBB-targeted therapies have shown limited efficacy.

How can phospho-EFNB1 (Y317) be used as a biomarker in cancer research?

Phospho-EFNB1 (Y317) has potential applications as a biomarker in cancer research contexts:

• Therapeutic resistance prediction: Detection of phospho-EFNB1 (Y317) levels before and during EGFR-targeted therapy could help predict and monitor the development of resistance .

• HPV-associated cancer characterization: Given that HPV16 E6 mediates degradation of PTPN13 (which regulates EFNB1 phosphorylation), elevated phospho-EFNB1 (Y317) could serve as a downstream biomarker of HPV oncogene activity .

• Treatment response monitoring: Changes in phospho-EFNB1 levels could provide early indication of treatment efficacy before clinical outcomes are apparent.

• Patient stratification: Phospho-EFNB1 status might identify patient subgroups more likely to benefit from combination therapies targeting both EGFR and EFNB1 signaling pathways.

Methodologically, researchers can assess phospho-EFNB1 (Y317) levels through several approaches, including:

• Western blot analysis of tumor biopsies

• Immunohistochemistry on tissue microarrays

• Phosphoproteomic analysis of patient samples

• Development of clinically applicable ELISA-based detection methods

How can I distinguish between different phosphorylation sites on EFNB1?

EFNB1 contains multiple tyrosine phosphorylation sites, including Y317, Y324, Y329, and Y331, creating challenges for site-specific analysis. Researchers can employ these strategies:

• Phospho-specific antibodies: Use antibodies that specifically recognize individual phosphorylation sites. For instance, anti-phospho-Y317 EFNB1 antibodies detect endogenous levels of EFNB1 protein only when phosphorylated at Tyr317 .

• Phosphorylation site mutants: Generate EFNB1 constructs with point mutations at specific tyrosine residues (Y→F mutations) to prevent phosphorylation at individual sites for functional studies.

• Mass spectrometry: For comprehensive phosphorylation site analysis, immunoprecipitate EFNB1 followed by mass spectrometry to quantitatively assess phosphorylation at each site.

• Comparative antibody analysis: Use multiple phospho-specific antibodies in parallel experiments to compare phosphorylation patterns across different sites and conditions .

When interpreting results, it's important to note that different phosphorylation sites may have distinct functional consequences and may be regulated by different kinases and phosphatases.

What are the key considerations for successful immunoprecipitation of phosphorylated EFNB1?

Successful immunoprecipitation (IP) of phosphorylated EFNB1 requires attention to several technical details:

• Lysis buffer composition: Use a lysis buffer containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, sodium pyrophosphate) to preserve phosphorylation. Research protocols suggest buffer compositions such as:

  • 50mM Tris HCl pH 7.5, 150mM NaCl, 5mM EDTA, 2mM Na₃VO₄, 100mM NaF, 10mM NaPPi, 10% glycerol, 1% Triton X-100, supplemented with protease inhibitor cocktail

• Antibody selection:

  • For IP of all EFNB1 forms: Use antibodies against non-phosphorylated epitopes

  • For phosphorylation-specific IP: Use phospho-specific antibodies

  • Example: Anti-ephrinB1 antibody (R&D Systems, AF473) has been successfully used for IP

• Cell preparation: Consider cell synchronization to control for cell cycle-dependent phosphorylation differences .

• Temperature control: Maintain samples at 4°C throughout the procedure to minimize phosphatase activity.

• Detection strategy: For western blot detection after IP, use phospho-specific antibodies to detect phosphorylated forms or pan-EFNB1 antibodies to detect total protein.

How can I assess the interaction between EFNB1 and microtubules in research settings?

The interaction between EFNB1 and microtubules, particularly at the mitotic spindle, can be investigated through multiple experimental approaches:

• Co-immunoprecipitation:

  • Immunoprecipitate EFNB1 and probe for tubulin (α/β tubulin, γ tubulin)

  • Consider comparing soluble (S) and insoluble (I) fractions, as well as mitotic (M) fractions

  • Example protocol: Cells can be synchronized by serum starvation and release, followed by mitotic shake-off to enrich for mitotic cells

• Microtubule binding assays:

  • In vitro microtubule assembly with purified proteins

  • Compare supernatant and pellet fractions after centrifugation

  • Include proper controls such as MAP2 (positive control) and BSA (negative control)

• Immunofluorescence microscopy:

  • Use antibodies recognizing different EFNB1 epitopes (intracellular, extracellular, phospho-specific)

  • Co-stain with tubulin markers (e.g., γ-tubulin for centrosomes)

  • Compare interphase vs. mitotic cells

• Live cell imaging:

  • Generate fluorescently tagged EFNB1 constructs (full-length and truncated versions)

  • Monitor localization during cell cycle progression

  • Consider photobleaching techniques to assess dynamics